Reports related to this article:
Project(s): View 4 related projects in PECWeb
Plant(s): View 4 related plants in PECWeb
en
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--California lives up to its "Golden State" nickname when it comes to the life-science industry. From complex university-based research centers to advanced biopharmaceutical manufacturing, the state continues to consistently attract major capital project dollars.
Click on the image at right for a graph detailing life-science projects set to kick off in 2015 in California, by county.
A recent survey taken from Industrial Info's Pharmaceutical-Biotech PECWEB Direct revealed 62 active projects with a total investment value (TIV) of $2.6 billion, scheduled to begin construction in 2015. In addition to this total, there are another 23 projects with a planned kick-off date after January 2016 that represent another $1.6 billion. Another 31 projects, valued at $3.2 billion, are in various stages of construction.
The 2015 projects carry an average TIV of $42 million. The projects include everything from a $1 million Biosafety Level-3 Laboratory addition in Irvine, to a $250 million grassroot intravenous therapeutics manufacturing plant in La Verne.
California is attractive for a variety of reasons, the least of which is not the sheer amount of intellectual property. This goes beyond the massive manufacturing and drug development campuses of commercial operations.
The statewide university system continuously invests hundreds of millions of dollars into research complexes. Even when state budgets are tight, there seems to be no shortage of munificent philanthropists willing to fund these projects. It becomes symbiotic as these research centers go on to attract top scientists, whose medical discoveries, in turn, could attract big pharma and bio dollars.
A look at just three of the 2015 projects illustrates the variety of life-science industry activity within the state. The sampling includes manufacturing, speculative investment and public research, all with TIVs no less than $180 million.
Gilead Sciences (NASDAQ:GILD) (Foster City, California) remains one of the state's favorites. The company is set to launch a $250 million project in LaVerne, California, to build a 400,000-square-foot plant and outfit it for the production, R&D and warehouse/distribution of intravenous and other biological therapeutics. Designed by Ferguson Pape Baldwin Architects (San Diego, California), Rudolph & Sletten is handling construction for the project, which also will add central utilities.
In addition to the LaVerne project, Gilead continues to invest millions of dollars into its Foster City campus. The company's 10-year master plan calls for a $400 million total investment in the site spread over multiple projects.
In San Diego, industry REIT giant BioMed Realty Trust (San Diego, California) has just begun construction of the $189 million I3 Speculative Research Campus. On a 7-acre site, within the University Town Centre (UTC) area, the company is constructing three 3-story, 100,000-square-foot buildings (LEED Platinum) and another 16,000-square-foot net-zero amenities building, for multiple life-science companies to perform various biotech and other high-tech R&D activities. The project team includes Perkins + Will Architects (Seattle, Washington) and McCarthy Building Companies (San Diego, California).
The U.S. Department of Veteran Affairs is planning to build a $180 million Basic Science Research Center with a vivarium in Palo Alto. Designed by Smithgroup Architects (San Francisco, California), the project will add a 143,000-square-foot building, with a 31,500-square-foot, basement-level vivarium for centralized interdisciplinary research of life sciences, including pathology, biology, chemistry and other related disciplines.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, three offices in North America and 10 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities.
Click on the image at right for a graph detailing life-science projects set to kick off in 2015 in California, by county.A recent survey taken from Industrial Info's Pharmaceutical-Biotech PECWEB Direct revealed 62 active projects with a total investment value (TIV) of $2.6 billion, scheduled to begin construction in 2015. In addition to this total, there are another 23 projects with a planned kick-off date after January 2016 that represent another $1.6 billion. Another 31 projects, valued at $3.2 billion, are in various stages of construction.
The 2015 projects carry an average TIV of $42 million. The projects include everything from a $1 million Biosafety Level-3 Laboratory addition in Irvine, to a $250 million grassroot intravenous therapeutics manufacturing plant in La Verne.
California is attractive for a variety of reasons, the least of which is not the sheer amount of intellectual property. This goes beyond the massive manufacturing and drug development campuses of commercial operations.
The statewide university system continuously invests hundreds of millions of dollars into research complexes. Even when state budgets are tight, there seems to be no shortage of munificent philanthropists willing to fund these projects. It becomes symbiotic as these research centers go on to attract top scientists, whose medical discoveries, in turn, could attract big pharma and bio dollars.
A look at just three of the 2015 projects illustrates the variety of life-science industry activity within the state. The sampling includes manufacturing, speculative investment and public research, all with TIVs no less than $180 million.
Gilead Sciences (NASDAQ:GILD) (Foster City, California) remains one of the state's favorites. The company is set to launch a $250 million project in LaVerne, California, to build a 400,000-square-foot plant and outfit it for the production, R&D and warehouse/distribution of intravenous and other biological therapeutics. Designed by Ferguson Pape Baldwin Architects (San Diego, California), Rudolph & Sletten is handling construction for the project, which also will add central utilities.
In addition to the LaVerne project, Gilead continues to invest millions of dollars into its Foster City campus. The company's 10-year master plan calls for a $400 million total investment in the site spread over multiple projects.
In San Diego, industry REIT giant BioMed Realty Trust (San Diego, California) has just begun construction of the $189 million I3 Speculative Research Campus. On a 7-acre site, within the University Town Centre (UTC) area, the company is constructing three 3-story, 100,000-square-foot buildings (LEED Platinum) and another 16,000-square-foot net-zero amenities building, for multiple life-science companies to perform various biotech and other high-tech R&D activities. The project team includes Perkins + Will Architects (Seattle, Washington) and McCarthy Building Companies (San Diego, California).
The U.S. Department of Veteran Affairs is planning to build a $180 million Basic Science Research Center with a vivarium in Palo Alto. Designed by Smithgroup Architects (San Francisco, California), the project will add a 143,000-square-foot building, with a 31,500-square-foot, basement-level vivarium for centralized interdisciplinary research of life sciences, including pathology, biology, chemistry and other related disciplines.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, three offices in North America and 10 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities.
